A critical review on Triple negative Breast cancer : Note on symptoms, Diagnosis and Prognosis

Abstract

Author(s): Eswari beeram*

By using technique immunohistochemistry (IHC); we can categorize Triple negative breast cancer (TNBC) as a diverse disease negative for receptors like human epidermal growth factor receptor 2 (HER2); progesterone receptor (PR); and estrogen receptor (ER). Young Adult age women and Hispanic women bearing BRCA1 gene mutation most commonly develop TNBC. Aggressiveness in tumours; molecular typing and lack of targeted therapies are the characteristic features of TNBC TNBC group of cancers are diverse and difficult to treat due to nonresponsive to hormonal therapy where it is the choice of treatment in other types of cancer. Chemotherapy; radiation and surgery are the first line treatment for therapy and additional targeted therapies form the basis for treating later stages of cancer when treatment is not possible with surgery and when the tumour spread is beyond to the localized area. TNBC differs from other related hormone positive cancers with a relapse of three to five years and with a significant drop thereafter.

Share this article